stockrowTango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
Follow TNGX
Alert me
Tango Therapeutics, Inc. (TNGX) P/S ratio
As of 5 November 2026, Tango Therapeutics, Inc. (TNGX) trades at a P/S ratio of 51.0×. Over the past ten years it has ranged from 0.0× (September 2021) to 75.7× (June 2026); the current reading is higher than 92% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 16.5× | 105.64% |
| FY2024 | 8.0× | (68.95%) |
| FY2023 | 25.8× | 0.06% |
| FY2022 | 25.8× | 40.78% |
| FY2021 | 18.3× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Dec 2025 | 16.5× | 17.70% |
| Sep 2025 | 14.0× | (39.83%) |
| Jun 2025 | 23.3× | 531.88% |
| Mar 2025 | 3.7× | (54.05%) |
| 17 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| PBLS Parabilis Medicines, Inc. compare | n/m |
| EWTX Edgewise Therapeutics, Inc. compare | n/m |
| IRON Disc Medicine, Inc. compare | n/m |
| ACAD ACADIA Pharmaceuticals Inc. compare | 3.1× |
| IOVA Iovance Biotherapeutics, Inc. compare | 9.3× |
| TNGX Tango Therapeutics, Inc. | 51.0× |
| ABCL AbCellera Biologics Inc. compare | 51.9× |
| XENE Xenon Pharmaceuticals Inc. compare | 223× |
| RLAY Relay Therapeutics, Inc. compare | 313× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on TNGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement